A Court Ruling on GLP-1 Ads, a Weekly Insulin for Kids, and Other Health Stories to Know

A U.S. judge rejected Novo Nordisk's request to temporarily block Eli Lilly from running ads claiming its weight-loss and diabetes drugs are more powerful. The same week, the FDA expanded approval for a once-weekly insulin for children ages 10 and older with type 2 diabetes. Studies also showed endocrinologists prescribing newer diabetes drugs more often and GLP-1 use among Medicare beneficiaries rising sharply. Here is a friendly rundown of what changed, what it means, and what to keep in mind.

A Court Ruling on GLP-1 Ads, a Weekly Insulin for Kids, and Other Health Stories to Know

A U.S. judge rejected Novo Nordisk's request to temporarily block Eli Lilly from running ads claiming its weight-loss and diabetes drugs are more powerful. The ruling does not settle anything about the products themselves. Separately, the FDA expanded approval of insulin icodec (Awiqli) for children ages 10 and older with type 2 diabetes.

Health news moved quickly this week, and several stories share a common thread: GLP-1 drugs. A U.S. judge rejected Novo Nordisk's request to temporarily block Eli Lilly from running advertisements that claim its weight-loss and diabetes drugs are more powerful. The ruling doesn't settle anything about the products themselves, but it shows how closely the two companies are competing for attention. If you have been wondering what all the noise is about, this guide walks through the highlights.

Did a Court Block Eli Lilly's GLP-1 Drug Ads?

Let's start with the ads. Novo Nordisk asked the court to pause Lilly's marketing while the dispute moved forward. The judge said no. For patients, the practical takeaway is simple: advertising claims about how strong a medication is deserve a closer look. Ask your healthcare provider which option fits your situation, and don't rely on a commercial alone.

A once-weekly insulin option for children

Is There a Once-Weekly Insulin for Children?

The FDA expanded its approval of insulin icodec, sold as Awiqli, making it the first once-weekly insulin indicated for type 2 diabetes in children ages 10 years and older. For families used to a more frequent dosing routine, a weekly schedule could change the day-to-day picture. It is still a conversation to have with a pediatric endocrinologist or your child's doctor, who can explain whether it suits your child's needs.

Prescribing habits are shifting too. After updates to American Diabetes Association guidelines, endocrinologists were more likely to prescribe SGLT2 inhibitors and GLP-1 receptor agonists for type 2 diabetes, according to a cross-sectional study published in JAMA Network Open. In other words, the guidelines seem to be reaching the clinic.

How Common Have GLP-1 Drugs Become?

Another JAMA Network Open study looked at how common these drugs have become. Among Medicare beneficiaries with type 2 diabetes, GLP-1 drug use surged more than 16-fold between 2010 and 2022. The researchers also found limited differences in that growth based on cancer history. Numbers like these help explain why the drugs now show up in beauty, advertising and policy conversations alike.

Other headlines worth a look

Beyond diabetes and weight loss, the fertility picture stood out. The U.S. fertility rate fell 1% in 2025 to a record low of 53.2 births per 1,000 females ages 15 to 44, according to CDC data. That is a sobering number, and it is one reason researchers and policymakers keep watching these trends closely.

A large Swedish cohort study published in JAMA Pediatrics found that autoimmune diseases during pregnancy were associated with a 57% higher risk of type 1 diabetes in offspring. An association is not the same as a cause, so the study is best read as a reason to stay informed and talk with your doctor about pregnancy health.

Weight and eating habits also made news. In a randomized trial, adding emotion-regulation skills to family-based behavioral treatment did not improve weight loss in adolescents with overweight or obesity. It was, however, associated with less weight regain and less emotional eating over 12 months. Meanwhile, lawmakers in at least 32 states have introduced bills to limit or eliminate ultraprocessed foods in school meals, according to the Washington Post.

The bottom line for readers is to separate headlines from details. Ads can be persuasive, studies can be early, and policies can change. When a story touches your health, bring your questions to a qualified clinician and use reliable sources to check what you read.

FAQ

Did a judge block Eli Lilly's GLP-1 drug ads?
No. A U.S. judge rejected Novo Nordisk's request to temporarily block Lilly from running the ads while the dispute moved forward.
Is there a once-weekly insulin approved for children?
The FDA expanded approval of insulin icodec, sold as Awiqli, making it the first once-weekly insulin indicated for type 2 diabetes in children ages 10 years and older.
Did adding emotion-regulation skills improve weight loss in adolescents?
No. In a randomized trial, adding these skills to family-based behavioral treatment did not improve weight loss, but it was associated with less weight regain and less emotional eating over 12 months.

Read next

Novo Nordisk Sues Eli Lilly Over 'Deceptive' GLP-1 Drug Ads

Novo Nordisk Sues Eli Lilly Over 'Deceptive' GLP-1 Drug Ads

Novo Nordisk has sued Eli Lilly, alleging the company's ad campaign for its obesity and diabetes drugs is 'deceptive' and uses 'outdated clinical trials' to make them appear more effective. The lawsuit, filed in federal court in New Jersey, claims Lilly is comparing high doses of its drugs to lower doses of Novo's similar medications.

Two Deaths Linked to Counterfeit Retatrutide; Novo Nordisk to Drop Saxenda

Two Deaths Linked to Counterfeit Retatrutide; Novo Nordisk to Drop Saxenda

Two recent deaths tied to counterfeit versions of retatrutide, an investigational weight-loss medication, have been reported to the Food and Drug Administration. The reports come as lawsuits against GLP-1 drugs continue, and as Novo Nordisk announced plans to discontinue its weight-loss injectable Saxenda in early 2027 because of declining sales. The World Health Organization also issued its first obesity guidelines for children and adolescents, and researchers released new findings on diabetes, dementia risk in women with PMOS, and a range of other conditions.